文献速递疼痛医学

持续模式失效后改用序贯柔性模式鞘内输注治疗难治性癌痛的回顾性随访研究

Sequential flex mode for intrathecal infusion after continuous mode failure: a retrospective follow-up study for refractory cancer pain management.
PubMed 文献 · Reg Anesth Pain Med · 2026-09-08

该回顾性单中心研究纳入53例持续模式高流速高日剂量下仍疼痛的难治性癌痛患者,评估序贯柔性模式(基础流速联合大剂量团注)的镇痛效果。结果显示71.7%±6.43%患者NRS降低至少30%,52.5%±7.12%的切换中NRS降低超过50%,中位NRS从6.4(SD 2.0)显著降至3.3(SD 2.2)(p<0.0001)。结论提示该模式可能在持续模式失效时提供更好镇痛并减少日剂量升级。

要点

  • 序贯柔性模式适用于持续模式高流速高日剂量下仍疼痛的难治性癌痛患者。
  • 切换后71.7%±6.43%患者NRS降低至少30%,中位NRS从6.4降至3.3(p<0.0001)。
  • 不良反应发生在59次切换中的12次(20.3%±6.06%),多为非严重性焦虑增加。

核心结论

  • 序贯柔性鞘内输注模式可能在持续模式失效时提供更好镇痛,并有助于减少每日剂量升级。

研究设计与样本

  • 回顾性单中心研究,纳入53例在持续高流速高日剂量下仍疼痛的难治性癌痛患者。

主要发现

  • 71.7%±6.43%的患者在序贯柔性模式下达到至少30%的NRS疼痛缓解。
  • 52.5%±7.12%的切换中疼痛缓解甚至超过50%的NRS降低。
  • 中位NRS评估显示切换后从6.4(SD 2.0)显著降至3.3(SD 2.2)(p<0.0001)。
  • 切换成功组中鞘内吗啡和罗哌卡因日剂量在切换前后保持稳定。
  • 59次切换中12次(20.3%±6.06%)出现不良反应,均为非严重性,最常见为焦虑增加。

关键数值与推荐

  • 序贯柔性模式仅用于持续高流速和高日剂量下仍疼痛的患者。
  • 序贯柔性模式定义为使用基础流速联合大剂量团注的输注模式。

临床怎么用

  • 对于已植入IDDS且持续模式高流速高日剂量下仍疼痛的难治性癌痛患者,可考虑切换至序贯柔性模式以改善镇痛。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intrathecal drug delivery systems (IDDS) have long been recommended to relieve intractable cancer pain. Intrathecal treatment administered by continuous flow rate can result in suboptimal analgesia, despite daily dosage escalation. The distribution of drugs in the cerebrospinal fluid remains limited during intrathecal infusion.Thus, despite catheter localization close to the target level in the intrathecal space, it is challenging to maintain effective therapy despite a considerable increase in continuous pump flow rate. This led to the consideration of how to cover more dermatomes with an already implanted IDDS. Literature suggests that using large boluses, in addition to conventional continuous infusion, may help intrathecal drug spread. An innovative infusion mode, defined as the sequential flex mode, using a basal flow rate with large boluses, could provide better pain relief than the usual continuous flow rate mode. METHODS: The sequential flex mode was used only for patients suffering despite a high continuous flow rate and a high daily drug dosage. The main objective of this retrospective monocentric study was to determine if patients achieved better pain relief with the sequential flex mode than the continuous flow rate mode. RESULTS: 53 patients were included. 71.7%±6.43% of the patients achieved at least 30% Numerical Rating Scale (NRS) pain reduction with the sequential flex mode, and in 52.5%±7.12% of the switches, the pain relief achieved was even greater than 50% NRS reduction. The median NRS evaluation showed a significant pain reduction after the switch from 6.4 (SD 2.0) to 3.3 (SD 2.2) (p<0.0001). Intrathecal morphine and ropivacaine daily doses remained stable in the switch success group around the switch. Adverse effects occurred in 12 switches out of 59 (20.3%±6.06%), and were non-serious in nature, most commonly increased anxiety. CONCLUSION: The sequential flex intrathecal infusion mode may provide better pain relief when the continuous mode loses efficacy, as well as help to reduce daily dosage escalation.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Bienfait F, Jubier-Hamon S, Seegers V, et al. Sequential flex mode for intrathecal infusion after continuous mode failure: a retrospective follow-up study for refractory cancer pain management. Reg Anesth Pain Med. 2026. PMID: 42710950. doi:10.1136/rapm-2025-107217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。